• 1
    Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 1998; 352: 14131418.
  • 2
    Rougier P, Van Cutsen E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 1998; 352: 14071412.
  • 3
    Cunningham D, Zalcberg J, Maroun J, et al. Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer. a review of phase II/III trials. Eur J Cancer. 2002; 38: 478486.
  • 4
    Aschele C, Baldo C, Sobrero AF, Debernardis D, Bornmann WG, Bertino JR. Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro. Clin Cancer Res. 1998; 4: 13231330.
  • 5
    Carnaghi C, Rimassa L, Garassino I, et al. Irinotecan and raltitrexed: an active combination in advanced colorectal cancer. Ann Oncol. 2002; 13: 14241429.
  • 6
    Aparicio J, Vicent JM, Maestu I, et al. Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer. Ann Oncol. 2003; 14: 11211125.
  • 7
    Feliu J, Salud A, Escudero P, et al. Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study. Br J Cancer. 2004; 90: 15021507.
  • 8
    Relling MV, Dervieux T. Pharmacogenetics and cancer therapy. Nat Rev Cancer. 2001; 1: 99108.
  • 9
    Ulrich CM, Robien K, McLeod HL. Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer. 2003; 3: 912920.
  • 10
    Nagasubramanian R, Innocenti F, Ratain MJ, et al. Pharmacogenetics in cancer treatment. Annu Rev Med. 2003; 54: 437452.
  • 11
    Innocenti F, Iyer L, Ratain MJ. Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan. Drug Metab Dispos. 2001; 29: 596600.
  • 12
    Ando Y, Saka H, Ando M, et al. Polymorphisms of UDP-glucoronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 2000; 60: 69216926.
  • 13
    Iyer L, Das S, Janisch L, et al. UGT1A1*28 pholimorphism as a determinant of irinotecan disposition and toxicity. Pharmocogenomics J. 2002; 2: 4347.
  • 14
    Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.. J Clin Oncol. 2004; 22: 13821388.
  • 15
    Marcuello E, Altes A, Menoyo A, del Rio E, Gomez-Pardo M, Baiget M. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer. 2004; 90: 15.
  • 16
    Rouits E, Boisdron-Celle M, Dumont A, Guerin O, Morel A, Gamelin E. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients.. Clin Cancer Res. 2004; 10: 51515159.
  • 17
    Bagley PJ, Selhub J. A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells. Proc Natl Acad Sci USA. 1998; 95: 1321713220.
  • 18
    Stevenson JP, Redlinger M, Kluijtmans L, et al. Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer. J Clin Oncol. 2001; 19: 40814087.
  • 19
    Farrugia DC, Ford HE, Cunningham D, et al. Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed. Clin Cancer Res. 2003; 9: 792801.
  • 20
    Horie N, Aiba H, Ogura K, et al. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct. 1995; 20: 191197.
  • 21
    Pullarkat ST, Stoehlmacher J, Ghaderi V, et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J. 2001; 1: 6570.
  • 22
    Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16: 3141.
  • 23
    Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5: 649655.
  • 24
    Brooks R. EuroQol: the current state of play. Health Policy. 1996; 37: 5372.
  • 25
    de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol. 1997; 15: 808815.
  • 26
    Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000; 355: 10411047.
  • 27
    de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18: 29382947.
  • 28
    Santini D, Massacesi C, D'Angelillo RM, et al. Raltitrexed plus weekly oxaliplatin as first-line chemotherapy in metastatic colorectal cancer: a multicenter non-randomized phase ii study.. Med Oncol. 2004; 21: 5966.
  • 29
    Mc Leod HL, Sargent DJ, Marsh S, et al. Pharmacogenetic analysis of systemic toxicity and response after 5-fluorouracil (5FU)/CPT-11, 5FU/oxaliplatin (oxal), or CPT11/oxal therapy for advanced colorectal cancer (CRC): results from an intergroup trial. Presented at the American Society of Clinical Oncology Annual Meeting, Chicago, IL, May 31-June 3, 2003.
  • 30
    Meyerhardt JA, Kwok A, Ratain MJ, et al. Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer. J Clin Oncol. 2004; 22: 14391446.
  • 31
    Schaaf LJ, Rothenberg ML, Hammond LA, et al. Phase I trial of weekly irinotecan (CPT11) in patients with hepatic dysfunction [abstract 402]. Proc Am Soc Clin Oncol. 2001; 20: 402.
  • 32
    Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2000; 343: 905914.
  • 33
    Vanhoefer U, Harstrick A, Achterrath W, et al. Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol. 2001; 19: 15011518.
  • 34
    Massacesi C, Santini D, Rocchi M, et al. Raltitrexed-induced hepatotoxicity: multivariate analysis of predictive factors. Anticancer Drugs. 2003; 14: 533541.
  • 35
    Barnes EA, Bruera E. Fatigue in patients with advanced cancer: a review. Int J Gynecol Cancer. 2002; 12: 424428.
  • 36
    Aparicio T, Desrame J, Lecomte T, et al. Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly. Br J Cancer. 2003; 89: 14391444.